Side Effects of Synvisc (hylan G-F 20)

Synvisc (hylan G-F 20) is an injectable fluid used to treat osteoarthritis (OA) of the knee. Osteoarthritis is a type of arthritis where the body’s joints degenerate, causing pain and stiffness. It is the most common form of arthritis. Joints contain synovial fluid, which acts as a lubricant and shock absorber.

In patients with osteoarthritis, the synovial fluid becomes thinner and less effective as a lubricant and shock absorber. Synvisc, made from a substance called hyaluronan found in normal joint fluid, is an elastic fluid used to restore the shock-absorbing effect of the fluid in the knee. This can reduce pain and lead to a more active lifestyle.

Common side effects of Synvisc include:

• joint pain
• joint stiffness
• joint swelling
• headache
• flu-like symptoms
• back pain
• injection site reactions (pain, stiffness, redness)
• skin rash
• itching
• facial flushing
• facial swelling

Serious side effects of Synvisc include severe pain or swelling around the knee after injection.

No known drug interactions have been reported with Synvisc. Adequate studies have not been conducted on pregnant or breastfeeding women.

What are the important side effects of Synvisc (hylan G-F 20)?

About 1 in 14 persons experience pain or swelling in the injected knee, and one third of those who do, need to have fluid removed from the knee.

Common side effects include joint pain, joint stiffness, headache, joint swelling, flu-like symptoms, and back pain.

Other side effects include injection site pain, injection site stiffness, injection site redness, skin rash, itching, facial flushing, and facial swelling.

Synvisc (hylan G-F 20) side effects list for healthcare professionals

Potential Adverse Effects Of The Device On Health

Reported Device-Related Adverse Events

The most commonly reported adverse events associated with Synvisc (hylan G-F 20) are:

• Pain in the injected knee
• Swelling in the injected knee
• Joint effusion

Potential Adverse Events

The following adverse events may occur with intra-articular injections, including Synvisc (hylan G-F 20):

• Arthralgia
• Joint stiffness
• Joint effusion
• Joint swelling
• Joint warmth
• Injection site pain
• Arthritis
• Arthropathy
• Gait disturbance

Post-marketing experience with Synvisc (hylan G-F 20) has identified rare adverse events, including rash, hives, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia, peripheral edema, malaise, respiratory difficulties, flushing, and facial swelling. Thrombocytopenia has also been reported in rare cases.

Adverse Events

Adverse Events Involving the Injected Joint

• Clinical Trials: A total of 511 patients (559 knees) received 1771 injections in seven clinical trials of Synvisc (hylan G-F 20).
• There were 39 reports in 37 patients (2.2% of injections, 7.2% of patients) of knee pain and/or swelling after these injections.
• Ten patients (10 knees) were treated with arthrocentesis and removal of joint effusion.
• Two additional patients (two knees) received treatment with intra-articular steroids.
• Two patients (two knees) received NSAIDs. One of these patients also received arthrocentesis.
• One patient was treated with arthroscopy. The remaining patients with adverse events localized to the knee received no treatment or only analgesics.
• A total of 157 patients have received 553 injections in the three clinical trials of repeated courses of Synvisc (hylan G-F 20) treatment.
• The reports in these trials describe a total of 48 reports of adverse events localized to the injected knee in 35 patients that occurred after injections that patients had received during their second course of treatment.
• These adverse events accounted for 6.3% of injections in 22.3% of patients as compared to 2.2% of injections in 7.2% of patients in a single course of Synvisc (hylan G-F 20) injections.
• In addition, reports of two retrospective studies during the post-marketing period have described adverse events localized to the injected knee that have occurred after 4.4% and 8.5% of injections that patients had received during one or more repeated courses of Synvisc (hylan G-F 20) treatment.
• Post-market Experience: The most common adverse events reported have been pain, swelling, and/or effusion in the injected knee.
• In some cases, the effusion was considerable and caused pronounced pain.
• In some instances, patients have presented with knees that were tender, warm, and red. It is important to rule out infection or crystalline arthropathies in such cases. Synovial fluid aspirates of varying volumes have revealed a range of cell counts, from very few to over 50,000 cells/mm³.
• Reported treatments included symptomatic therapy (e.g., rest, ice, heat, elevation, simple analgesics, and NSAIDs) and/or arthrocentesis. Intra-articular corticosteroids have been used when infection was excluded. Rarely, arthroscopy has been performed.
• The occurrence of post-injection effusion may be associated with patient history of effusion, advanced stage of disease, and/or the number of injections or treatment courses a patient receives.
• Reactions generally abate within a few days.
• Clinical benefit from the treatment may still occur after such reactions.
• The clinical trials described above included 38 patients who received a second course of Synvisc (hylan G-F 20) injections (132 injections).
• There were twelve reports in nine patients (9.1% of injections, 23.7% of patients) of knee pain and/or swelling after these injections.
• Reports of two additional clinical trials in which patients received repeated courses of Synvisc (hylan G-F 20) treatment have appeared during the post-marketing period.
• One of these trials included 48 patients who received 210 injections during a second course of Synvisc (hylan G-F 20) treatment; the other contained 71 patients who received 211 injections during a second course of Synvisc (hylan G-F 20) treatment.
• Intra-articular infections did not occur in any of the clinical trials and have been reported only rarely during clinical use of Synvisc (hylan G-F 20).

Other Adverse Events

• Clinical Trials: In three controlled clinical trials with a total of 112 patients who received Synvisc (hylan G-F 20) and 110 patients who received either saline or arthrocentesis, there were no statistically significant differences in the numbers or types of adverse events between the two groups.
• Systemic adverse events occurred in 10 (2.0%) of the Synvisc (hylan G-F 20) treated patients.
• There was one case each of rash and itching of the skin following Synvisc (hylan G-F 20) injections in these studies.
• These symptoms did not recur when these patients received additional Synvisc (hylan G-F 20) injections.
• The remaining generalized adverse events reported were calf cramps, hemorrhoid problems, ankle edema, muscle pain, tonsillitis with nausea, tachyarrythmia, phlebitis with varicosities, and low back sprain.

Other adverse events reported include rash, hives, itching, fever, nausea, headache, dizziness, chills, muscle cramps, paresthesia, peripheral edema, malaise, respiratory difficulties, flushing, and facial swelling. Rare reports of thrombocytopenia have also been associated with Synvisc injections. The causal relationship to Synvisc is uncertain and these events are considered rare.

What drugs interact with Synvisc (hylan G-F 20)?

No information provided.

Summary

Synvisc (hylan G-F 20) is an injectable fluid used to treat osteoarthritis (OA) of the knee. Common side effects include joint pain, joint stiffness, joint swelling, headache, flu-like symptoms, back pain, injection site reactions (pain, stiffness, redness), skin rash, itching, facial flushing, and facial swelling. No known drug interactions have been reported with Synvisc. Adequate studies have not been conducted on pregnant or breastfeeding women.